Which antibiotics are safe to use in a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency who presents with fever and rash?

Antibiotic Safety in G6PD Deficiency with Fever and Rash

Most commonly used antibiotics—including penicillins (amoxicillin), cephalosporins, fluoroquinolones (ciprofloxacin), and trimethoprim-sulfamethoxazole at standard doses—are safe for G6PD-deficient patients presenting with fever and rash. 1, 2, 3

High-Risk Antibiotics to Absolutely Avoid

Only seven medications carry definitive evidence of causing hemolysis in G6PD deficiency, and among antibiotics, these include: 3, 4

• Dapsone – potent oxidant causing methemoglobinemia and hemolysis 5, 3
• Nitrofurantoin – though recent evidence suggests lower risk than previously thought 6
• Primaquine – antimalarial, not typically used for fever/rash 3

The other contraindicated agents (methylene blue, rasburicase, phenazopyridine, tolonium chloride) are not antibiotics used for fever/rash presentations. 3, 4

Safe First-Line Antibiotics for Fever and Rash

Beta-Lactams (Safest Category)

• Amoxicillin and other penicillins are explicitly not contraindicated and can be used in normal therapeutic doses 1, 7
• Cephalosporins (ceftriaxone, cefepime, ceftazidime) have no evidence contraindicating their use 8, 3
• Carbapenems (meropenem, imipenem) are safe options 8, 3

Fluoroquinolones

• Ciprofloxacin has been prescribed safely to hundreds/thousands of G6PD-deficient patients in real-world data 2
• Ofloxacin – despite package warnings, literature review shows only poorly documented cases of hemolysis 9

Sulfonamide-Containing Antibiotics (Use with Caution but Generally Safe)

• Trimethoprim-sulfamethoxazole (TMP-SMX) at standard doses rarely causes hemolysis in G6PD-deficient populations 10, 11
  • A controlled study of 20 G6PD-deficient patients receiving high-dose TMP-SMX (50 mg/kg/day sulfamethoxazole) showed zero cases of hemolysis 10
  • Prophylactic doses in pediatric oncology patients showed no increased hemolysis risk 11
  • Real-world data from 31,962 G6PD-deficient patients showed safe prescribing 2
• Sulfasalazine has been prescribed safely in real-world cohorts 2

Clinical Decision Algorithm

For a G6PD-deficient patient with fever and rash:

1. First-line empiric choices (no G6PD concerns):

   • Amoxicillin or amoxicillin-clavulanate for community-acquired infections 1
   • Ceftriaxone or other cephalosporins for broader coverage 8
   • Ciprofloxacin for specific indications 2

2. Avoid absolutely:

   • Dapsone (if considering for dermatologic conditions) 5, 3
   • Nitrofurantoin (if considering for UTI) – though risk may be overstated 6

3. Use with standard precautions (no special G6PD monitoring needed):

   • TMP-SMX can be used at therapeutic doses 10, 11
   • Fluoroquinolones are safe despite historical warnings 2, 9

Evidence Reconciliation: The Nitrofurantoin Controversy

Nitrofurantoin warrants special discussion because guidelines list it as contraindicated 3, yet recent evidence suggests the risk is minimal:

• Only 42 confirmed cases of hemolysis in G6PD-deficient patients out of 245 million exposures worldwide 6
• Real-world data showed 1,366 G6PD-deficient patients safely prescribed nitrofurantoin 2
• A 200 mg daily dose for 3-5 days may be acceptable without G6PD screening when accompanied by appropriate warnings 6

Clinical recommendation: While technically contraindicated, if nitrofurantoin is the only effective option for a resistant UTI, the absolute risk is very low. However, safer alternatives (amoxicillin, cephalosporins) should be preferred for fever/rash presentations. 2, 6

Monitoring Recommendations

For any antibiotic in G6PD deficiency, educate patients to recognize hemolysis signs: 5

• Dark/cola-colored urine
• Sudden fatigue or pallor
• Jaundice
• Back or abdominal pain

Baseline testing before starting potentially risky antibiotics: 12

• Complete blood count with hemoglobin
• Consider repeat testing if acute hemolysis suspected, as G6PD levels may be falsely elevated during crisis 1

Variant-Specific Considerations

• Mediterranean variant (G6PD-B⁻) carries higher risk of severe hemolysis and requires stricter precautions 5, 4
• African variant (G6PD-A⁻) typically produces milder, self-limited hemolysis 12, 5
• These distinctions matter less for the safe antibiotics listed above, but are critical if considering sulfonamides or other medium-risk agents 4

Common Pitfall to Avoid

Many drugs have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes, not because the drug itself caused hemolysis. 3 The fever and infection itself can trigger hemolysis in G6PD deficiency, independent of antibiotic choice. This historical confusion has led to overly restrictive warnings for many safe antibiotics. 2, 3